Delayed bile leak with avastin after liver resection for metastatic colorectal cancer

Hepato-Gastroenterology

Volumn 58, Issue 110-111, 2011, Pages 1769-1770

  Lordan, Jeffrey T ^a   Wilkins, Marie ^b   Karanjia, Nariman D ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b Sussex Cancer Network   (United Kingdom)

Author keywords

Avastin; Bevacizumab; Bile leak; Hepatectomy; Liver resection; Surgery

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN;

ABSCESS DRAINAGE; ADJUVANT THERAPY; ADULT; ARTICLE; BILE DUCT DILATATION; BILE LEAKAGE; BILIARY TRACT DRAINAGE; CANCER ADJUVANT THERAPY; CASE REPORT; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEVER; HISTOPATHOLOGY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; LAPAROTOMY; LIVER HEMANGIOMA; LIVER METASTASIS; LIVER RESECTION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; MULTIPLE CYCLE TREATMENT; PLEURA EFFUSION; PRIORITY JOURNAL; SPHINCTEROTOMY; STENT; SUBPHRENIC ABSCESS; THORAX DRAINAGE; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BILE; BILIARY TRACT DISEASES; CHEMOTHERAPY, ADJUVANT; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; REOPERATION;

EID: 83355163493     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hwang S, Lee SG, Lee YJ, et al.: Postoperative changes in remnant medial segment parenchyma of living donor livers after procurement of left lateral segment graft. Hepato-Gastroenterology 2006; 53:773-777. (Pubitemid 44683000)
2. Karanjia ND, Lordan JT, Fawcett WJ, et al.: Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases - a ten year study. European Journal of Surgical Oncology 2009; 35:838-843.
3. Lordan JT, Karanjia ND, Quiney N, et al.: Survival after systemic chemotherapy and liver resection for colorectal metastases; a ten year audit. HPB 2008; 10(S1)65.
4. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345. (Pubitemid 38944402)
5. Giantonio BJ, Levy DE, O'dwyer PJ, et al.: A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. [Clinical Trial, Phase II. Journal Article. Multicenter Study. Research Support, N.I.H., Extramural]. Annals of Oncology 2006; 17:1399-1403. (Pubitemid 44400378)
6. Hochester HS: Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Seminars in Oncology 2006; 33:S8-S14.
7. Hofheinz RD, Horisberger K, Woernle C, et al.: Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. [Clinical Trial, Phase I. Journal Article]. International Journal of Radiation Oncology, Biology, Physics. 2006; 66:1384-1390.
8. Saif MW, Rang SP, Chu E: Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. Oncology 2006; 2011-19.
9. de Gramont A, Figer A, Seymour M: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947. (Pubitemid 30644117)
10. Douillard JY, Cunningham D, Roth AD: Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer:a multicentre randomised trial. Lancet 2000; 355:1041-1047. (Pubitemid 30162806)
11. Giacchetti S, Perpoint B, Zidani R: Phase III multicentre randomised trial of oxaliplatin added tp chronomodulated fluorouracil-leocovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147. (Pubitemid 30036347)
12. Goldberg RM, Sargent DJ, Morton RF: A randomised controlled trial of fluorouracil plus leucovorin, irinotecan, oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30. (Pubitemid 41095110)
13. Saltz LB, Cox JV, Blanke C: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914.
14. Lordan JT, Karanjia ND, Quiney N, et al.: A ten year prospective audit of liver resection for colorectal metastases in a tertiary referral unit. Br J Surg 2007; 94 (S5)2.
15. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371:1007-1016. (Pubitemid 351392040)
16. D'Angelica M, Kornprat P, Gonen M, et al.: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007; 14:759-765. (Pubitemid 46175324)
17. Saif MW, Mehra R: Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert opinion on drug safety 2006; 5:553-566. (Pubitemid 44468452)